Molecular, cellular, and tissue responses following photodynamic therapy.
Photodynamic therapy (PDT) is being utilized in the treatment of a wide variety of malignant tumors. Results using PDT have been encouraging, and controlled clinical trials are currently being performed. The procedure exploits both the tumor-localizing and -photosensitizing properties of hematoporphyrin derivative or its purified component, Photofrin II. When this porphyrin mixture is administered systemically, it is retained preferentially in tumor tissue as compared to surrounding normal tissue. Localized tumor destruction induced by PDT results from the photochemical generation of cytotoxic oxygen species within the tumor. This review will provide a summary of historical and current research pertaining to molecular, cellular, and tissue responses induced by PDT. Emphasis is placed on information related to the chemistry of current photosensitizers, subcellular targets, preclinical treatment parameters, and clinical responses following PDT.
Gomer
C J
CJ
Clayton Ocular Oncology Center, Children's Hospital of Los Angeles.
Ferrario
A
A
Hayashi
N
N
Rucker
N
N
Szirth
B C
BC
Murphree
A L
AL
D000818:Animals; D002417:Cattle; D017323:Dihematoporphyrin Ether; D004353:Drug Evaluation, Preclinical; D004354:Drug Screening Assays, Antitumor; D017324:Hematoporphyrin Derivative; D006414:Hematoporphyrin Photoradiation / Q000639:trends*; D006415:Hematoporphyrins / Q000276:immunology / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D053685:Laser Therapy; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D010777:Photochemistry; D010778:Photochemotherapy / Q000639:trends*; D011817:Rabbits; D051381:Rats
D006415:Hematoporphyrins; D017324:Hematoporphyrin Derivative; D017323:Dihematoporphyrin Ether